Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02447874 · ClinicalTrials.gov registry record · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
A Phase 1 study of Sickle Cell Disease, sponsored by Emory University.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
- 2
- Study locations
NCT02447874 is a Phase 1 study of Sickle Cell Disease that is actively recruiting participants, run by Emory University. The registered enrollment target is 21 participants, below the 293-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (93% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT02447874, a Phase 1 study of Sickle Cell Disease, is actively recruiting participants, sponsored by Emory University.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to determine whether giving extra arginine to patients with sickle cell disease seeking treatment for vaso-occlusive painful events (VOE) will decrease pain scores, decrease need for pain medications or decrease length of hospital stay or emergency department visit.
Conditions Studied
Interventions
- DRUG Arginine
- DRUG Arginine (Loading)
- DRUG Arginine (Continuous)
Study Locations (2)
Georgia
- Children's Healthcare fo Atlanta at Hughes Spalding - Atlanta
- Children's Healthcare of Atlanta at Arthur M. Blank Hospital - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2015-05 |
| Est. Completion | 2026-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02447874
The ClinicalTrials.gov registry entry for NCT02447874 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 293-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (93% lower). The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Sickle Cell Disease appearing as the primary indexed condition, and to 3 interventions - of which Arginine is the first listed.
NCT02447874 reports 2 study locations spanning 1 distinct geographic area - top geographies include Georgia.
Frequently Asked Questions
What is clinical trial NCT02447874 about?
NCT02447874 is a clinical study titled "Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease". The purpose of this study is to determine whether giving extra arginine to patients with sickle cell disease seeking treatment for vaso-occlusive painful events (VOE) will decrease pain scores, decrease need for pain medications or decrease length of hospital stay or emergency department visit.
What is the current status of trial NCT02447874?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2015-05. Estimated completion is 2026-07.
What conditions does trial NCT02447874 study?
This clinical trial studies the following conditions: Sickle Cell Disease.
What interventions are being tested in trial NCT02447874?
The interventions under investigation include: Arginine (DRUG), Arginine (Loading) (DRUG), Arginine (Continuous) (DRUG).
Who is sponsoring clinical trial NCT02447874?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02447874 being conducted?
This trial has 2 study locations across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sickle Cell Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
RECRUITING · Phase 1
-
Hematopoietic Stem Cell BCL11A Enhancer Gene Editing for Severe β-Hemoglobinopathies
RECRUITING · Phase 1
-
Gene Correction in Autologous CD34+ Hematopoietic Stem Cells (HbS to HbA) to Treat Severe Sickle Cell Disease
RECRUITING · Phase 1
-
PET Imaging of Vaso-Occlusive Crisis (VOC) in SCD
RECRUITING · Phase 1
-
Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects With Stable Sickle Cell Disease
RECRUITING · Phase 1
-
Methylphenidate to Address Attention and Executive Deficits Among Children With Sickle Cell Disease
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.